These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 30659302)

  • 1. Role of androgen receptor splice variants, their clinical relevance and treatment options.
    Wach S; Taubert H; Cronauer M
    World J Urol; 2020 Mar; 38(3):647-656. PubMed ID: 30659302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
    Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
    Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
    Eur Urol; 2017 Apr; 71(4):680-687. PubMed ID: 27733296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.
    Ho Y; Dehm SM
    Endocrinology; 2017 Jun; 158(6):1533-1542. PubMed ID: 28368512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
    Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M; Antonarakis ES; Luo J
    Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
    Sowalsky AG; Figueiredo I; Lis RT; Coleman I; Gurel B; Bogdan D; Yuan W; Russo JW; Bright JR; Whitlock NC; Trostel SY; Ku AT; Patel RA; True LD; Welti J; Jimenez-Vacas JM; Rodrigues DN; Riisnaes R; Neeb A; Sprenger CT; Swain A; Wilkinson S; Karzai F; Dahut WL; Balk SP; Corey E; Nelson PS; Haffner MC; Plymate SR; de Bono JS; Sharp A
    Clin Cancer Res; 2022 Aug; 28(16):3509-3525. PubMed ID: 35695870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
    Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP
    Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
    Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
    Shao C; Yu B; Liu Y
    Life Sci; 2019 Oct; 234():116768. PubMed ID: 31445027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
    Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
    Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
    De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
    Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
    Antonarakis ES; Chandhasin C; Osbourne E; Luo J; Sadar MD; Perabo F
    Oncologist; 2016 Dec; 21(12):1427-1435. PubMed ID: 27628492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
    Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
    Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
    J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
    Lu C; Brown LC; Antonarakis ES; Armstrong AJ; Luo J
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):381-397. PubMed ID: 32139878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.
    Shafi AA; Cox MB; Weigel NL
    Steroids; 2013 Jun; 78(6):548-54. PubMed ID: 23380368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.